anti-hyperlipidemic agent
Jump to navigation
Jump to search
Notes
- combination of low-dose statin plus either a bile acid sequestrant or ezetimibe reduces LDL cholesterol more than high-dose statin monotherapy[1]
- long-term clinical benefits uncertain
More general terms
More specific terms
- bile acid sequestrant
- cholesterol absorption inhibitor
- cholesteryl ester transfer protein (CETP) inhibitor
- combination antihyperlipidemic agent/therapy
- dextrothyroxine (Cholixin)
- evacetrapib
- evinacumab-dgnb (Evkeeza)
- fibrate
- HMG CoA reductase inhibitor (statin)
- inositol hexaniacinate ('No flush' niacin)
- lepodisiran
- lomitapide (Juxtapid)
- LY295427
- mipomersen (Kynamro)
- nicotinic acid (niacin, vitamin B3, Niaspan)
- oxandrolone (Oxandrin)
- PCSK9 inhibitor (ALN-PCS)
- policosanol
- probucol (Lorelco)
- rimonabant (Acomplia, Zimulti)
Additional terms
- hypercholesterolemia
- hyperlipoproteinemia (HLP)
- hypertriglyceridemia
- lipid panel (fasting lipid panel, FLP)
References
- ↑ 1.0 1.1 Gudzune KA, Monroe AK, Sharma R et al Effectiveness of Combination Therapy With Statin and Another Lipid-Modifying Agent Compared With Intensified Statin Monotherapy: A Systematic Review. Ann Intern Med. Published online 11 February 2014 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/24514899 <Internet> http://annals.org/article.aspx?articleid=1828554